Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.

Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH.

Ann Oncol. 2014 Jan;25(1):132-8. doi: 10.1093/annonc/mdt489.

2.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team.

Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.

PMID:
24331154
3.

Chemotherapy control by breath profile with application of SPME-GC/MS method.

Ulanowska A, Trawińska E, Sawrycki P, Buszewski B.

J Sep Sci. 2012 Nov;35(21):2908-13. doi: 10.1002/jssc.201200333. Epub 2012 Sep 24.

PMID:
23001965
4.

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators.

N Engl J Med. 2012 Feb 16;366(7):601-9. doi: 10.1056/NEJMoa1108898.

5.

Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia.

Tzekova V, Mihaylov G, Elezovic I, Koytchev R; Epoetin Zeta Oncology Study Group.

Curr Med Res Opin. 2009 Jul;25(7):1689-97. doi: 10.1185/03007990903050876.

PMID:
19505200
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk